Biologics Outsourcing Market Report 2026

Biologics Outsourcing Market Overview

• Biologics Outsourcing market size has reached to $22.58 billion in 2025 • Expected to grow to $42.43 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Surge In Cancer Cases Fuels Biologics Outsourcing Market Growth • Market Trend: Cutting-Edge Contract Development And Manufacturing Organization • North America was the largest region in 2025.

What Is Covered Under Biologics Outsourcing Market?

Biologics outsourcing refers to pharmaceutical companies partnering with external vendors or contract manufacturing organizations (CMOs) to outsource various aspects of biologic drug development, manufacturing, and supply chain management. This is used in the pharmaceutical industry for different purposes related to biological drug development, manufacturing, and supply chain management. The main product types of biologics outsourcing are antibodies, recombinants, vaccines, proteins, and others. Antibodies refer to an immune system-produced defense protein known as an antigen that is created in reaction to the presence of foreign material. The various sources include human, microbial, and others, and are applied over oncology, cellular and gene therapy, blood and blood-related product development, vaccine development, stem cell research, and others used by various end users such as pharmaceutical industries, biotechnology industries, and contract development and manufacturing organization (CDMO).

What Is The Biologics Outsourcing Market Growth Forecast?

The biologics outsourcing market size is expected to see rapid growth in the next few years. It will grow to $42.43 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to increasing demand for large-scale biologics production, rising investments in multi-product manufacturing sites, expansion of cell and gene therapy outsourcing, growing focus on supply chain resilience, increasing adoption of digital manufacturing platforms. Major trends in the forecast period include increasing strategic outsourcing of biologic manufacturing, rising demand for end-to-end outsourcing services, growing preference for flexible manufacturing partnerships, expansion of global cdmo networks, enhanced focus on cost and risk optimization.

Global Biologics Outsourcing Market Segmentation

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products 2) By Source: Human, Microbial, Other Sources 3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications 4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization (CDMO) Subsegments: 1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies 2) By Recombinant: Recombinant Proteins, Recombinant DNA Products 3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines 4) By Protein: Enzymes, Hormones, Cytokines 5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

What Is The Driver Of The Biologics Outsourcing Market?

The rising number of cancer cases is expected to propel the growth of the biologics outsourcing market going forward. Cancer is a broad category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Biologics outsourcing plays a significant role in cancer cases by providing specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies, including monoclonal antibodies, immunotherapies, and other targeted biologics that are used for the diagnosis, treatment, and management of various types of cancer. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, there were 1,958,310 new cancer cases in the United States, and 609,820 cancer deaths are projected to occur in 2023. Further, the number of new cancer cases per year is expected to rise to 29.5 million and the number of cancer-related deaths to 16.4 million by 2040. Therefore, the rising number of cancer cases is driving the growth of the biologics outsourcing industry.

Key Players In The Global Biologics Outsourcing Market

Major companies operating in the biologics outsourcing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Global Biologics Outsourcing Market Trends and Insights

Major companies operating in the biologics outsourcing market are focusing on the developing of a new CDMOs to sustain their position in the market. A contract development and manufacturing organization (CDMO) is a company that provides pharmaceutical and biotechnology companies with a variety of services related to the development and manufacturing of drugs and other therapeutic products. For instance, in October 2023, Tanvex BioPharma USA Inc., a US-based developer and manufacturer of biopharmaceuticals, introduced Tanvex CDMO. This newly launched arm of the company provides end-to-end services for the development and manufacturing of biologics, catering to the needs of the biopharmaceutical industry. Located in San Diego’s Sorrento Valley biotech hub, Tanvex CDMO boasts a 100,000-square-foot facility, featuring a state-of-the-art Research and Development (R&D) center, two mammalian Good Manufacturing Practice (GMP) manufacturing suites, one microbial GMP manufacturing suite, Quality Control (QC) laboratories, and a GMP warehouse. Leveraging Tanvex BioPharma USA Inc.’s proven track record, Tanvex CDMO aims to assist early-stage companies in advancing mammalian and microbial-derived biologics from conceptualization to commercialization, providing a significant boost to the field of novel biologics and biosimilars.

What Are Latest Mergers And Acquisitions In The Biologics Outsourcing Market?

In December 2023, Ajinomoto Co., Inc., a Japan-based biotechnology corporation, acquired Forge Biologics for an undisclosed amount. With this acquisition, Ajinomoto aims to expand its global biologics outsourcing footprint and enhance its technological capabilities in cell and gene therapy development and commercial-scale manufacturing to better support pharmaceutical and biotechnology clients. Forge Biologics is a US-based provider of outsourced biologics services specializing in adeno-associated virus (AAV) vector development, preclinical to commercial-scale gene therapy manufacturing, and analytical and regulatory support services for biopharma companies.

Regional Outlook

North America was the largest region in the biologics outsourcing market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Biologics Outsourcing Market?

The biologics outsourcing market includes revenues earned by entities through cell line development, contract research services, and optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Biologics Outsourcing Market Report 2026?

The biologics outsourcing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the biologics outsourcing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.